PUBLISHER: IMARC | PRODUCT CODE: 1701859
PUBLISHER: IMARC | PRODUCT CODE: 1701859
The global prefilled syringes market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.8 Billion by 2033, exhibiting a growth rate (CAGR) of 7.58% during 2025-2033. At present, Europe holds the largest market share across the globe due to the increasing demand for biologics, a growing preference for convenient and safe self-administration, and stringent regulatory standards promoting the adoption of advanced, contamination-free drug delivery systems.
A prefilled syringe is a single-dose packet of injectable vaccines that is disposable in nature. The usage of prefilled syringes significantly lowers the chances of drug contamination as it avoids the potential admixture-related contamination risks when syringes are inserted into a drug vial to draw out a dose. Combining this with a pre-sterilized syringe further increases safety, enables the easy and quick delivery of drugs in the case of emergencies, and eliminates the additional on-site vial cleaning and de-pyrogenation processes. Consequently, they are a preferred option to administer the drugs via the parenteral route for delivering a wide range of injectables, such as biosimilar and biologics.
The global market is primarily driven by the increasing incidences of chronic diseases, including diabetes and autoimmune diseases. This is further supported by the growing demand for treating chronic medical conditions using biological drugs in pre-fillable syringes. In addition to this, the widespread adoption of the prefilled syringe products by healthcare professionals and the escalating number of new product launches by key players are also fostering the market. Moreover, with significant technological advancements, the implementations of self-injecting parenteral devices are also increasing, which, in turn, is contributing to the market growth. The market is also driven by the rising geriatric population on the global level and growing investments in improving the overall healthcare infrastructure. Other factors, such as supportive government regulations regarding needlestick legislation, the rising consciousness regarding the advantages of prefilled syringes, the widespread preference for home-based healthcare, and the increasing popularity of biologics and biosimilars across the pharmaceutical settings, are further creating lucrative growth opportunities in the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Cardinal Health Inc., Catalent Inc., Fresenius SE & Co. KGaA, Gerresheimer AG, Nipro Corporation, Schott AG, Terumo Corporation and West Pharmaceutical Services Inc.